Quay Pharma has underlined its position as a major player in the global pharmaceutical contract development and manufacturing (CDMO) sector with the creation of a US subsidiary.
Quay Pharmaceuticals LLC has now opened an office in the CIC shared space resource in Cambridge, at the heart of the Massachusetts Biotech community, a few months ahead of the opening of a dedicated facility for development and manufacturing.
Quay has achieved a strong US presence in the last three years and the new operational facility in the Greater Boston area will be able to support the scaling up of products from Phase II to Phase III and the commercialisation of small and large molecules, as well as live biotherapeutics for oral and topical delivery.
“The current coronavirus pandemic has clearly demonstrated the need for a fast response and accelerated development of new drugs, which is where CDMOs have a vital role,” commented Quay CEO Maireadh Pedersen.
“Global capabilities need to be accompanied by localised support. Our new office in the US will not only enhance our work on existing projects for our customers but with the manufacturing operation, we will also have the flexibility to undertake clinical trials in Europe and the US from either facility.”
Established in 2002, Quay Pharma has become one of the world’s leading CDMOs offering a complete service through all stages of drug development and clinical supply as well as pre-qualification batches to support Marketing Authorisation applications and initial manufacture of commercial product.
In recent years, the company has pioneered work in live biotherapeutics for oral and topical delivery, being the first UK clinical contracting company to be licensed for live biotherapeutic manufacture for finished products. Quay is also one of the few CDMOs developing many types of biologics and microbial therapies for oral drug delivery and manufacture.